The tissue and circulating cell-free DNA-derived genetic landscape of premalignant colorectal lesions and its application for early diagnosis of colorectal cancer

Abstract

Colorectal adenomas (CRAs) represent precancerous lesions that precede the development of colorectal cancer (CRC). Regular monitoring of CRAs can hinder the progression into carcinoma. To explore the utility of tissue DNA and circulating cell-free DNA (cfDNA) in early diagnosis of CRC, we retrospectively sequenced paired tissue and plasma samples from 85 patients with conventional CRAs. The genetic alterations identified were compared with those from 78 stage-I CRC patients (CRC-I) in the ChangKang project. Within the CRA cohort, we pinpointed 12 genes, notably APC, KRAS, and SOX9, that exhibited significant mutated rates in tissue. Patients harboring KMT2C and KMT2D mutations displayed persistent polyps. By comparing with the mutational profiles of metastatic CRC plasma samples, we found that ZNF717 was exclusively mutated in CRAs, while KMT2C and KMT2D mutations were detected in both CRA and CRC. The presence of cfDNA mutations in plasma was validated through polymerase chain reaction, enhancing the feasibility of using cfDNA mutations for early CRC screening. Compared with CRC-I, CRAs exhibited a reduced frequency of TP53 and PIK3CA somatic mutations and underwent non-neutral evolution more often. We established a random forest model based on 15 characteristic genes to distinguish CRA and CRC, achieving an area under the curve of 0.89. Through this endeavor, we identified two novel genes, CNTNAP5 and GATA6, implicated in CRC carcinogenesis. Overall, our findings reveal convincing biomarkers markers for detecting CRAs with a propensity for CRC development, highlighting the importance of early genetic screening in CRC prevention.

Keywords

circulating cell-free DNA / colorectal adenomas / colorectal cancer / premalignant lesions

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-249.

[2] Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. New Engl J Med. 1988; 319(9): 525-532.

[3] Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487(7407): 330-337.

[4] Zhao Q, Wang F, Chen YX, et al. Comprehensive profiling of 1015 patients’ exomes reveals genomic-clinical associations in colorectal cancer. Nat Commun. 2022; 13(1): 2342.

[5] Lin SH, Raju GS, Huff C, et al. The somatic mutation landscape of premalignant colorectal adenoma. Gut. 2017; 67(7): 1299-1305.

[6] Cross W, Kovac M, Mustonen V, et al. The evolutionary landscape of colorectal tumorigenesis. Nat Ecol Evol. 2018; 2(10): 1661-1672. doi:10.1038/s41559-018-0642-z

[7] Strum WB. Colorectal adenomas. New Engl J Med. 2016; 374(11): 1065-1075.

[8] Chen B, Scurrah CR, McKinley ET, et al. Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps. Cell. 2021; 184(26): 6262-6280.

[9] Druliner BR, Wang P, Bae T, et al. Molecular characterization of colorectal adenomas with and without malignancy reveals distinguishing genome, transcriptome and methylome alterations. Sci Rep. 2018; 8(1): 3161.

[10] Chang K, Willis JA, Reumers J, et al. Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2. Ann Oncol. 2018; 29(10): 2061-2067.

[11] Komor MA, Bosch LJ, Bounova G, et al. Consensus molecular subtype classification of colorectal adenomas. J Pathol. 2018; 246(3): 266-276.

[12] Teixeira VH, Pipinikas CP, Pennycuick A, et al. Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions. Nat Med. 2019; 25(3): 517-525.

[13] Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic—implementation issues and future challenges. Nat Rev Clin Oncol. 2021; 18(5): 297-312.

[14] Song P, Wu LR, Yan YH, et al. Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. Nat Biomed Eng. 2022; 6(3): 232-245.

[15] Xu RH, Wei W, Krawczyk M, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater. 2017; 16(11): 1155-1161.

[16] Wang DS, Liu ZX, Lu YX, et al. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut. 2019; 68(7): 1152-1161.

[17] Luo H, Zhao Q, Wei W, et al. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020; 12(524).

[18] Wang F, Huang YS, Wu HX, et al. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut. 2021;71(7):1340-1349.

[19] Bao H, Wang Z, Ma X, et al. Letter to the Editor: an ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection. Mol Cancer. 2022; 21(1): 129.

[20] Ma X, Chen Y, Tang W, et al. Multi-dimensional fragmentomic assay for ultrasensitive early detection of colorectal advanced adenoma and adenocarcinoma. J Hematol Oncol. 2021; 14(1): 175.

[21] Junca A, Tachon G, Evrard C, et al. Detection of colorectal cancer and advanced adenoma by liquid biopsy (decalib study): the ddPCR challenge. Cancers (Basel). 2020; 12(6).

[22] Myint NNM, Verma AM, Fernandez-Garcia D, et al. Circulating tumor DNA in patients with colorectal adenomas: assessment of detectability and genetic heterogeneity. Cell Death Dis. 2018; 9(9): 894.

[23] Cai G, Cai M, Feng Z, et al. A multilocus blood-based assay targeting circulating tumor DNA methylation enables early detection and early relapse prediction of colorectal cancer. Gastroenterology. 2021; 161(6): 2053-2056.

[24] Van den Eynden J, Fierro AC, Verbeke LP, Marchal K. SomInaClust: detection of cancer genes based on somatic mutation patterns of inactivation and clustering. BMC Bioinformatics. 2015; 16: 125.

[25] Martinez-Jimenez F, Muinos F, Sentis I, et al. A compendium of mutational cancer driver genes. Nat Rev Cancer. 2020; 20(10): 555-572.

[26] Soussi T, Wiman KG. TP53: an oncogene in disguise. Cell Death Differ. 2015; 22(8): 1239-1249.

[27] Baker AM, Cross W, Curtius K, et al. Evolutionary history of human colitis-associated colorectal cancer. Gut. 2019; 68(6): 985-995.

[28] Hu X, Fujimoto J, Ying L, et al. Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. Nat Commun. 2019; 10(1): 2978. doi:10.1038/s41467-019-10877-8

[29] Shen R, Seshan VE. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 2016; 44(16): e131.

[30] Dewhurst SM, McGranahan N, Burrell RA, et al. Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution. Cancer Discov. 2014; 4(2): 175-185.

[31] Duan M, Hao J, Cui S, et al. Diverse modes of clonal evolution in HBV-related hepatocellular carcinoma revealed by single-cell genome sequencing. Cell Res. 2018; 28(3): 359-373.

[32] Wang F, Huang Y-S, Wu H-X, et al. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut. 2022; 71(7): 1340-1349.

[33] Kato S, Lippman SM, Flaherty KT, Kurzrock R. The conundrum of genetic “drivers” in benign conditions. J Natl Cancer Inst. 2016; 108(8).

[34] Sanchez-Vega F, Mina M, Armenia J, et al. Oncogenic signaling pathways in the cancer genome atlas. Cell. 2018; 173(2): 321-337. doi:10.1016/j.cell.2018.03.035

[35] Perne C, Peters S, Cartolano M, et al. Variant profiling of colorectal adenomas from three patients of two families with MSH3-related adenomatous polyposis. PLoS One. 2021; 16(11): e0259185.

[36] Rashid M, Fischer A, Wilson CH, et al. Adenoma development in familial adenomatous polyposis and MUTYH-associated polyposis: somatic landscape and driver genes. J Pathol. 2016; 238(1): 98-108.

[37] Thomas LE, Hurley JJ, Meuser E, et al. Burden and profile of somatic mutation in duodenal adenomas from patients with familial adenomatous-and MUTYH-associated polyposis. Clin Cancer Res. 2017; 23(21): 6721-6732.

[38] Williams MJ, Werner B, Barnes CP, Graham TA, Sottoriva A. Identification of neutral tumor evolution across cancer types. Nat Genet. 2016; 48(3): 238-244.

[39] Saito T, Niida A, Uchi R, et al. A temporal shift of the evolutionary principle shaping intratumor heterogeneity in colorectal cancer. Nat Commun. 2018; 9(1): 2884. doi:10.1038/s41467-018-05226-0

[40] Chen Q, He Z, Lan A, Shen X, Wen H, Wu CI. Molecular evolution in large steps—Codon substitutions under positive selection. Mol Biol Evol. 2019; 36(9): 1862-1873.

[41] Martincorena I, Raine KM, Gerstung M, et al. Universal patterns of selection in cancer and somatic tissues. Cell. 2017; 171(5): 1029-1041.

[42] Chen B, Scurrah CR, McKinley ET, et al. Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps. Cell. 2021; 184(26). doi:10.1016/j.cell.2021.11.031

[43] Chakraborty S, Sharma A, Sharma A, Sihota R, Bhattacharjee S, Acharya M. Haplotype-based genomic analysis reveals novel association of CNTNAP5 genic region with primary angle closure glaucoma. J Biosci. 2021; 46: 15.

[44] Chakraborty S, Sarma J, Roy SS, et al. Post-GWAS functional analyses of CNTNAP5 suggests its role in glaucomatous neurodegeneration. bioRxiv. 2024:583830.

[45] Zhang Y, Goss AM, Cohen ED, et al. A Gata6-Wnt pathway required for epithelial stem cell development and airway regeneration. Nat Genet. 2008; 40(7): 862-870.

[46] Whissell G, Montagni E, Martinelli P, et al. The transcription factor GATA6 enables self-renewal of colon adenoma stem cells by repressing BMP gene expression. Nat Cell Biol. 2014; 16(7): 695-707.

[47] Tsuji S, Kawasaki Y, Furukawa S, et al. The miR-363-GATA6-Lgr5 pathway is critical for colorectal tumourigenesis. Nat Commun. 2014; 5: 3150.

[48] Chen Z, Qi Y, He J, et al. Distribution and characterization of extrachromosomal circular DNA in colorectal cancer. Mol Biomed. 2022; 3(1): 38.

[49] Martignano F, Munagala U, Crucitta S, et al. Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients. Mol Cancer. 2021; 20(1): 32.

[50] Huang J-q, Luo H-y. Impact of genome and epigenome on intratumor heterogeneity in colorectal cancer. MedComm—Fut Med. 2023; 2(1): e34.

[51] Hu Y-T, Chen X-F, Zhai C-B, et al. Clinical evaluation of a multitarget fecal immunochemical test-sDNA test for colorectal cancer screening in a high-risk population: a prospective, multicenter clinical study. MedComm. 2023; 4(4): e345.

[52] Mendelaar PAJ, Smid M, van Riet J, et al. Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features. Nat Commun. 2021; 12(1): 574.

[53] Huang KK, Ramnarayanan K, Zhu F, et al. Genomic and epigenomic profiling of high-risk intestinal metaplasia reveals molecular determinants of progression to gastric cancer. Cancer Cell. 2018; 33(1): 137-150.

[54] Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14): 1754-1760.

[55] Koboldt DC, Zhang Q, Larson DE, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012; 22(3): 568-576.

[56] Kim S, Scheffler K, Halpern AL, et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat Methods. 2018; 15(8): 591-594.

[57] Zhang Z, Yin L, Hao L, et al. GVC: an ultra-fast and all-round genome variant caller. bioRxiv. 2019:182089. doi:10.1101/182089

[58] Qiu M-Z, Chen Q, Zheng D-Y, et al. Precise microdissection of gastric mixed adeno-neuroendocrine carcinoma dissects its genomic landscape and evolutionary clonal origins. Cell Rep. 2023; 42(6): 112576.

[59] Yang H, Wang K. Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR. Nature protocols. 2015; 10(10): 1556-1566.

[60] Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018; 28(11): 1747-1756.

[61] Chen Q, Wu Q-N, Rong Y-M, et al. Deciphering clonal dynamics and metastatic routines in a rare patient of synchronous triple-primary tumors and multiple metastases with MPTevol. Brief Bioinform. 2022; 23(5): bbac175.

[62] Chen Q, Lan A, Shen X, Wu CI. Molecular evolution in small steps under prevailing negative selection: a nearly universal rule of codon substitution. Genome Biol Evol. 2019; 11(10): 2702-2712.

[63] Rashid M, Fischer A, Wilson CH, et al. Adenoma development in familial adenomatous polyposis and MUTYH-associated polyposis: somatic landscape and driver genes. J Pathol. 2016; 238(1).

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.